The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Solid Tumor, Advanced Solid Tumor
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Study of PYX-201 in Solid Tumors
-
HonorHealth Research Institute, Scottsdale, Arizona, United States, 85258
SCRI - HealthOne Denver, Denver, Colorado, United States, 80218
SCRI - Florida Cancer Specialists, Sarasota, Florida, United States, 34232
University of Chicago Medicine, Chicago, Illinois, United States, 60637
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110-1010
Rhode Island Hospital, Providence, Rhode Island, United States, 02903
NEXT Dallas, Dallas, Texas, United States, 75231
NEXT San Antonio, San Antonio, Texas, United States, 78229
NEXT Virginia, Fairfax, Virginia, United States, 22031
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Pyxis Oncology, Inc,
2027-05